Blinatumomab (Blincyto®)
Blincyto® is indicated for the treatment of adults with Philadelphia chromosome negative (Ph-) relapsed or refractory
B-precursor acute lymphoblastic leukaemia.
| NCPE Assessment Process | Completed |
| Rapid review received | 08/12/2015 |
| Rapid review completed | 22/12/2015 |
| Rapid Review outcome | Full Pharmacoeconomic Evaluation Not Recommended. The NCPE cannot recommend reimbursement of Blinctyo® at this point in time. |
| Following submission of new evidence | Full Pharmacoeconomic Evaluation Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 11/04/2017 |
| Pre-submission consultation with Applicant | 27/06/2017 |
| Anticipated date of submission | July 2017 |
| Submission received from applicant | 30/08/2017 |
| Preliminary review sent to applicant | 05/12/2017 |
| NCPE assessment re-commenced | 08/02/2018 |
| Factual accuracy sent to Applicant | 16/03/2018 |
| NCPE assessment re-commenced | 10/04/2018 |
| NCPE assessment completed | 16/04/2018 |
| Full pharmacoeconomic assessment outcome | The NCPE recommends that blinatumomab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013 |
The HSE has approved reimbursement following confidential price negotiations; May 2019